California-based Therna Biosciences has announced its launch with the stated vision to transform the development of RNA ...

Chinese biopharma Akeso has presented the final analysis of the Phase III HARMONi-A lung cancer study of ivonescimab, ...

US antivirals specialist Gilead Sciences yesterday announced that the European Commission (EC) has granted marketing ...

Regeneron Pharmaceuticals’ shares closed up 2.7% to $587.65 as it announced that the primary and key secondary endpoints were ...

The European Commission (EC) has approved Chinese biopharma Bio-Thera Solutions BAT2206 (ustekinumab), a biosimilar ...

A clinical-stage biotech company headquartered in San Diego, focused on advancing RNA-based medicines for serious and ...

Hot on the heels of European Commission approval for its film-coated Brukinsa (zanubrutinib) this week, Sino-American oncology-focused biotech BeOne Medicines’ today revealed that the EC has ...

Netherlands-based Scenic Biotech has announced a license and research agreement with Alnylam Pharmaceuticals to leverage Scenic’s Cell-Seq platform for discovering novel targets for RNAi therapeutics.

Eisai and Biogen have announced that the anti-amyloid beta (Aβ) monoclonal antibody Leqembi (lecanemab) was launched in ...

Center for Biologics Evaluation and Research (CBER) has suspended the biologics license for Valneva’s Ixchiq (Chikungunya ...

US pharm major AbbVie has signed a deal to acquire Gilgamesh Pharmaceuticals’ lead investigational candidate, currently in ...

The US Food and Drug Administration (FDA) has broadened the approved use of Amgen’s Repatha (evolocumab) to include adults at ...